Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex with Dose-Intense Temozolomide in Recurrent Glioblastoma
NCT01812603Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabis extract in glioblastoma (GBM), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Incidence of adverse events. Started Sep 2013; status: completed.
02
Drugs
cannabis extract
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01812603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812603.